GENEVA, SWITZERLAND--(Marketwire - December 17, 2008) - Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 as a migraine prevention therapy in people who suffer from 3 or more migraine attacks per month. ADX10059 is a first-in-class migraine prophylactic which works by inhibiting the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM). Addex believes mGluR5 may be a key player in a neural process that initiates migraine headaches. Thus, this approach -- inhibiting mGluR5 -- may lead to a new class of drugs that addresses the causes of migraine rather than just treating the symptoms.
